Objective: To study the value of serum NGAL and HE4 content change for diagnosing non-small cell lung cancer (NSCLC) and evaluating disease progression. Methods: Patients who were diagnosed with NSCLC and underwent surgical resection in the First Affiliated Hospital of Chengdu Medical College between February 2015 and March 2017 were selected as the NSCLC group, and healthy volunteers who received physical examination over the same period were selected as control group. The NGAL and HE4 contents in serum of NSCLC group and control group as well as the expression of proliferation, apoptosis and invasion genes in NSCLC lesion of NSCLC group were detected. Results: Serum NGAL and HE4 levels of NSCLC group were significantly higher than those of control group, serum NGAL and HE4 levels of patients with TNM II and TNM III NSCLC were significantly higher than those of patients with TNM I NSCLC, and serum NGAL and HE4 levels of patients with TNM III NSCLC were significantly higher than those of patients with TNM II NSCLC;c-myc, Survivin, CatL, Vimentin, Slug and Snail mRNA expression in NSCLC lesion were significantly higher than those in adjacent lesion and positively correlated with serum NGAL and HE4 levels while PTEN, LATS1 and E-cadherin mRNA expression were significantly lower than those in adjacent lesion and negatively correlated with serum NGAL and HE4 levels. Conclusion: Abnormally elevated NGAL and HE4 in the serum of NSCLC patients can evaluate the proliferation and invasion of cancer cells to a certain extent.
目的研究上皮膜蛋白2(epithelial membrane protein 2,EMP2)在多种人类肿瘤中的蛋白表达谱,并在小鼠乳腺癌模型中研究EMP2多肽疫苗的预防及治疗效果。方法采用大样本组织芯片检测人体常见20种肿瘤中,EMP2在正常组织与相对应的肿瘤组织的表达。体外化学合成EMP2多肽,并与KLH蛋白偶联。于小鼠接瘤前后免疫Balb/c小鼠,ELISA法检测免疫后小鼠抗EMP2抗体的血清效价。建立4T1细胞荷瘤小鼠预防及治疗模型,随机分为生理盐水组、单纯KLH组、单纯佐剂组、KLHEMP2多肽组,每组各10只。观察KLH-EMP2多肽疫苗对乳腺癌模型的成瘤率、肿瘤生长情况、体重及生存期的影响。结果与相应正常组织比较,EMP2在乳腺癌、子宫内膜癌、卵巢癌、宫颈癌、膀胱癌、甲状腺癌等肿瘤中明显高表达。而在胰腺癌、前列腺癌及脑部肿瘤中呈低表达或阴性表达。KLH-EMP2多肽免疫小鼠后,构建小鼠乳腺癌4T1荷瘤模型,对照组成瘤率为100%,佐剂组及单纯KLH组成瘤率分别为100%,100%,KLH-EMP2多肽组成瘤率为70%。较之对照组、佐剂组及单纯KLH组,KLHEMP2多肽组可明显抑制4T1肿瘤生长(P=0.009)。同时,延长荷瘤小鼠生存时间(P=0.001),同时,免疫对小鼠的体重无明显变化(P=0.58)。在4T1肿瘤治疗模型中,KLH-EMP2多肽治疗可明显抑制4T1肿瘤生长(P=0.001)和大小(P=0.006)。同时,延长4T1荷瘤小鼠生存期(P=0.03)。结论EMP2在乳腺癌中呈高表达,EMP2多肽疫苗具有明显的乳腺癌预防及治疗作用。
